1 ontinuous complete remission for >/=5 years)
was achieved in 3%.
2 aseline inducible VT, and VT noninducibility
was achieved in 69%.
3 freedom from recurrent AF/atrial tachycardia
was achieved in 87%.
4 Elimination of the targeted VT
was achieved in 90%.
5 Under rate control, rate criteria
were achieved in 96%.
6 tion was fast and the adsorption equilibrium
was achieved in 30min.
7 ied success (IOP </=21 mmHg with medication)
was achieved in 35.
0% and 7.5%, respectively (P = 0.003)
8 success (IOP </=21 mmHg without medication)
was achieved in 35.
0% eyes of the ALPI group compared wi
9 uccess (IOP </=21 mm Hg without medications)
was achieved in 60.
0% eyes of the SLT group, compared wi
10 Virological eradication/control
was achieved in 34.
1% of HCV and 88.6% of HBV patients a
11 Possible sustained unresponsiveness
was achieved in 82.
1% receiving PPOIT and 3.6% receiving
12 A final BCVA of 20/40 or better
was achieved in 6/
10 (60%) of eyes.
13 e 16-week regimen with and without ribavirin
was achieved in 26 (
100% [95% CI 87-100]) of 26 particip
14 Major molecular response
was achieved in 43% (
100 mg once daily) and 40% (all oth
15 SVR12
was achieved in 70% (
101/145) versus 68% (100/146) of pr
16 Complete response
was achieved in 65% (
11 of 17) of patients at minimum fo
17 At week 52, treatment success
was achieved in 3 (
12%) placebo-treated participants, 11
18 undetectable at end of treatment, and SVR12
was achieved in 102/
120 (85%) patients, with 7 relapses,
19 Postoperative CDVA of 20/20 and 20/30
was achieved in 75% (
15 eyes) and 25% (5 eyes), respecti
20 R0, R1, and R2 resections
were achieved in 78,
15, and 7 cases, respectively.
21 In the IMCT group, 360-degree cannulation
was achieved in 80% (
16/20) of eyes.
22 he per-protocol (PP) analysis, adjusted-ACPR
was achieved in 100% (
165/165) and 93.6% (161/172) of pa
23 Clinical success at 28 days
was achieved in 49% (
18/37) of patients who received ant
24 Complete hematological remission
was achieved in 153/
180 (85%) patients and 27 (15%) died
25 Confirmed objective response
was achieved in 52 (
19.6%, 95% CI 15.0-24.9) of 265 pati
26 Overall sustained viral response
was achieved in 122/
199 patients, 46/109 infected by dif
27 Viral consensus sequences can
be achieved in 1-
2 d by starting with clinical samples a
28 Driving vision (20/40 or better)
was achieved in 43.
2% of treated eyes.
29 pid international normalized ratio reduction
was achieved in 62.
2% of patients receiving 4F-PCC versu
30 canalization with the balloon guide catheter
was achieved in 89.
2% of thrombectomies (91 of 102) vers
31 dex limb at 30 days (+ 7 days) postprocedure
was achieved in 99.
2% (258/260) of patients (P < 0.001).
32 giographic, procedural, and clinical success
was achieved in 99.
2%, 99.1%, 98.3%, and 96.6% of cases,
33 Absent, incomplete, and complete STR
were achieved in 514 (
20.7%), 712 (28.7%), and 1258 (50.
34 pCR
was achieved in 19% (
21 of 111) of cases; 86% of them we
35 Successful epicardial ablation
was achieved in 5 (
22%) patients.
36 med investigator-assessed objective response
was achieved in 19 (
24.4%, 95% CI 15.3-35.4) of 78 patie
37 Freedom from AF
was achieved in 21/
26 (81%) at 6 months off antiarrhythm
38 Among GT3-infected patients, SVR12
was achieved in 96% (
27 of 28; 95% CI, 82-99) of patient
39 Gross total resection (GTR)
was achieved in 16/
27 (59.3%) patients, subtotal resecti
40 Confirmed objective response
was achieved in 23 (
28.4%, 95% CI 18.9-39.5) of the 81 p
41 is suppurativa clinical response at 12 weeks
was achieved in 30% (
3 of 10) of the placebo arm and in
42 Ablation of the clinical VT only
was achieved in 18.
3% of ICM and in 22.2% of NIDCM patie
43 Procedural success
was achieved in 99.
3% and 96.6% of BRS- and DES-treated
44 Patient benefit
was achieved in 12 (
30.0%; 95% CI 16.6-46.5) patients gi
45 HIV testing
was achieved in 131,
307 (89%) of 146,906 adults with sta
46 durable reduction in MR to </=2+ at 30 days
was achieved in 5 (
33.3%) of the first 15 patients and 1
47 Complete clinical success
was achieved in 259 (
37%) of 705 patients, with a wide v
48 Significant enhancement of potency
was achieved in 5-(
4-aminobutyl)-N(4)-butyl-6-methylpyri
49 ity during programmed electrical stimulation
was achieved in 34.
4% and 19.2% of patients, respectivel
50 Bacterial identification
was achieved in 43.
4%.
51 xcellent outcome (modified Rankin Score 0-1)
was achieved in 47.
4% (236/498) of direct patients versu
52 Effective hemostasis
was achieved in 72.
4% of patients receiving 4F-PCC versu
53 eek 48, HIV-1 RNA less than 50 copies per mL
was achieved in 92.
4% of patients (n=290 of 314) in the
54 A likely molecular diagnosis
was achieved in 110 (
40%) unrelated probands.
55 At week 16, a PASI 75 response
was achieved in 37 (
41%) patients in the methotrexate gr
56 of approaches, a confirmed genetic diagnosis
was achieved in 51% (
43 of 85).
57 Favorable overall response
was achieved in 113 (
46.5%) patients by week 2.
58 Diabetes remission
was achieved in 68 (
46%) participants in the interventio
59 Confirmed objective responses
were achieved in 18 (
47% [95% CI 31-64]) patients in the
60 Complete resection
was achieved in 86.
5% of patients (n = 697) in ADC, 69.5
61 gradient reduction to </=20 and </=10 mm Hg
was achieved in 89.
5% (95% confidence interval, 83.7-95.
62 ection of congenital intrahepatic bile ducts
was achieved in 90.
5% of the 148 patients who underwent
63 Relief from pressure-related symptoms
was achieved in 98.
5%, and durable remission of anemia a
64 -121 months) were recruited, and a diagnosis
was achieved in 23 (
52%) by singleton WES.
65 Complete clinical response
was achieved in 492 (
52%) of 940 patients at assessment
66 Overall acute success
was achieved in 16 (
53%) patients.
67 ntact to device activation within 90 minutes
was achieved in 913 (
54.1%) patients.
68 Rapid INR reduction
was achieved in 48 (
55%) patients in the 4F-PCC group co
69 Clinical success
was achieved in 40/
55 (73%) patients treated with minocy
70 Freedom from AF or AT
was achieved in 44 (
56%), 39 (48%), and 61 (74%) patient
71 1% or greater, confirmed objective responses
were achieved in 12 (
57%) of 21 patients in the ipilimum
72 At week 16, PASI75
was achieved in 22 (
58%) of 38 patients in the adalimuma
73 the 160 patients, and TICI 2b-3 reperfusion
was achieved in 94 (
59%) patients.
74 Clinical success
was achieved in 70.
59% of eyes in the ipsilateral group
75 virologic response at posttreatment week 12
was achieved in 100% (
6/6, 95% confidence interval 61-10
76 Complete remission
was achieved in 40% (
6/15 of evaluable patients) and med
77 A molecular diagnosis
was achieved in 62.
6% of patients with CMT attending the
78 reatment-free interval of 3 months or longer
was achieved in 92.
6% and 83.5% of the patients randomiz
79 Complete VT noninducibility
was achieved in 62 (
61%) patients and partial success or
80 Haematocrit control
was achieved in 46 (
62%) of 74 ruxolitinib-treated patie
81 ents and pharmacological control of symptoms
was achieved in 141 (
64%) patients.
82 Successful sustained ablation (SSA)
was achieved in 53 (
66%) patients, and LVEF improved in
83 Stage II palliation
was achieved in 92 (
67%) patients (Sano: 7; Norwood: 51;
84 d in six (3%) patients and partial responses
were achieved in 134 (
67%) patients.
85 s, single-procedure arrhythmia-free survival
was achieved in 58.
7% of patients.
86 ucibility of any clinical and nonclinical VT
was achieved in 66.
7% of NIDCM and in 77.4% of ICM patie
87 Adequate glycemic control (HbA1c < 7%)
was achieved in 66.
7% of the patients.
88 Ocular surface stability
was achieved in 72.
7% (120/165) of eyes at last follow-u
89 The area of interest
was achieved in 80.
7% of the cases, with a 5.5% rate of
90 At 1 year, absolute success
was achieved in 86.
7% (26/30) and 90.0% (27/30) in Group
91 SVR12
was achieved in 94.
7% (18 of 19), 97.6% (40 of 41), and
92 Adequate anesthesia and akinesia (grade 5)
were achieved in 56.
7% of the patients in the bupivacain
93 and transection of the anatomic isthmus and
was achieved in 25 (
74%) patients.
94 An R0 margin
was achieved in 36 (
74%) patients.
95 Retinal reattachment
was achieved in 10 (
76%) eyes after the first operation
96 f 23 patients, and device success at 30 days
was achieved in 18 (
78%) patients.
97 In the phase 2 part, an overall response
was achieved in 29 (
78% [95% CI 62-91]) of 37 patients.
98 ), an overall response by independent review
was achieved in 85 (
79.4%; 95% CI 70.5-86.6) of 107 pati
99 Angiographic CR
was achieved in 52.
8% of the PCI arm and 66.9% of the CA
100 SVR
was achieved in 56.
8% (95% confidence interval [CI]: 45.
101 Effectiveness
was achieved in 67.
8% and 69.4% of subjects in the CF an
102 itiating infliximab, control of inflammation
was achieved in 81.
8% at 6 months and in 88.9% at the 1-
103 Sixty-nine patients started treatment; SVR24
was achieved in 55 (
80% [95% confidence interval, 68%-88
104 tinal attachment after silicone oil removal)
was achieved in 20 (
83.3%) eyes at the end of follow-up,
105 with FNAB, a successful cytologic diagnosis
was achieved in 176 (
84%).
106 CI
was achieved in 37 (
84%) and led to better VT-free survi
107 e pulmonary vein (PV) isolation with CB only
was achieved in 99.
86% and 100% of veins with CBG1 and C
108 t within 6 months without further treatment,
was achieved in 29 (
87.9%) eyes.
109 Acute success
was achieved in 66 (
88%) patients in group 1, 68 (81%) i
110 Primary stricture resolution rate
was achieved in 17 (
89.5%) of 19 patients.
111 At week 48, HIV-1 RNA <50 copies per mL
was achieved in 286 (
89%) of 320 participants in the bic
112 erilization of the operative specimen, which
was achieved in 13.
9% versus 19.2% of patients, respecti
113 Control
was achieved in 38.
9% of intervention and 39.1% of contr
114 Complete necrosis
was achieved in 50.
9% and 57.1% of cTACE and DEB-TACE pa
115 Noninducibility of targeted VT
was achieved in 75.
9% of patients.
116 0 g) and nonoptimal CF groups, effectiveness
was achieved in 75.
9% versus 58.1%, respectively (P=0.01
117 imary patency at 12 months (360 +/- 30 days)
was achieved in 78.
9% (180/228) of the population (P < 0
118 ollow-up was 2 years, and complete follow-up
was achieved in 99.
9% of patients.
119 Effective haemostasis
was achieved in 78 (
90%) patients in the 4F-PCC group co
120 Disease control
was achieved in 21 (
91%; 95% CI 72.0-98.9) of 23 patient
121 improvement of best-corrected visual acuity
was achieved in 22 (
91.7%) eyes.
122 The primary endpoint
was achieved in 151 (
92%) participants with latent yaws
123 SVR12
was achieved in 154 (
92%) patients (n=72 [90%, 95% CI 81
124 Results Primary technical success
was achieved in 33 (
92%) patients who underwent a single
125 irological response (SVR) at week 12 (SVR12)
was achieved in 78% (
92 of 118) of patients (95% confide
126 and uprifosbuvir with and without ribavirin
was achieved in 39 (
93% [95% CI 81-99]) of 42 participan
127 Results Complete ablation
was achieved in 40 (
93%; 95% CI: 85, 100) of 43 target t
128 nd of therapy, sustained virologic responses
were achieved in 89%,
93%, 91%, and 86% of the patients
129 ydro-1,2,4-benzothiadiazine-1,1-dioxides has
been achieved in 39-
94% yield through palladium-catalyze
130 compassionate use cohort, technical success
was achieved in 22 (
96%) of 23 patients, and device succ
131 e 12-week regimen with and without ribavirin
was achieved in 28 (
97% [95% CI 82-100]) of 29 of those
132 Among treatment completers, SVR12
was achieved in 441 (
97.1%) of PPI recipients compared w
133 SVR12
was achieved in 57 (
97%; 97.5% CI 86.7-99.2) of 59 patie
134 e 12-week regimen with and without ribavirin
was achieved in 87 (
99% [95% CI 94-100]) of 88 participa
135 Disease control
was achieved in 81%,
although 38.5% had profound visual
136 centration with K. lactis beta-galactosidase
was achieved in 1 and 5h at 40 and 4 degrees C, respecti
137 idation of cryptocaryol A and cryptocaryol B
were achieved in 23 and 25 linear steps, respectively.
138 response 12 weeks after the end of treatment
was achieved in 95%
and 93% of the patients, respectivel
139 26, mucosal healing and endoscopic response
were achieved in 48%
and 65% of patients, respectively.
140 After ablation, complete LAVA elimination
was achieved in 60%,
and VT noninducibility in 83%.
141 ted animals, complete atrioventricular block
was achieved in 6 animals of all 4 dose groups (86%).
142 Confirmed major molecular response
was achieved in 64%
at 12 months and 73% at 24 months.
143 ET imaging shows that prominent tumor uptake
was achieved in 4T1 breast cancer with (64)Cu-LDH-BSA vi
144 Globe salvage
was achieved in 10 cases, as 1 patient required enucleat
145 Initial reattachment
was achieved in 139 cases (94.5%; 95% confidence interva
146 Final reattachment
was achieved in 147 cases (100%).
147 Postoperative BSCVA >/=20/25
was achieved in 14 eyes (38.9%), whereas a BSCVA of 20/3
148 Anatomical success
was achieved in 14 eyes.
149 Successful reattachment at 2 months
was achieved in 171 eyes (66.3%).
150 e resolution of fluid in and under the fovea
was achieved in 17 eyes (94%) without additional treatme
151 ional operation and final anatomical success
was achieved in 256 eyes (99.2%).
152 ision (defined as losing 5 letters or fewer)
was achieved in 28 eyes (90.3%).
153 27 eyes whose disease resolved, this result
was achieved in 4 eyes with medical treatment, in 7 pseu
154 Big bubble
was achieved in 5 eyes, while manual dissection was done
155 ry, 20/40 visual acuity or better (>/=20/40)
was achieved in 68%
following phacoemulsification, 72% f
156 H2O2 concentration of approximately 230 mg/L
was achieved in 6 h of batch cathode operation.
157 s, a complete resolution of subretinal fluid
was achieved in 26 half-fluence-treated eyes (83.9%) and
158 Technical success
was achieved in 85%
in fTRA and 86% in TFA (P=0.51).
159 Overall, a molecular diagnosis
was achieved in 102 infants (36.7%) by clinical exome se
160 sis of the putative structure of diplopyrone
was achieved in 17 linear steps starting from cis-1,4-bu
161 onvergent total synthesis of Leustroducsin B
was achieved in 17 longest linear and 39 total steps by
162 Reperfusion
was achieved in 27 LTB patients (67.5%) and 24 UTB patie
163 A baseline separation of the 20 phenolics
was achieved in 25 min with standard calibration curves
164 (acute retrieval cohort), complete retrieval
was achieved in 100% (
n=5/5); for those implanted for >/
165 Complete procedural success
was achieved in 50% (
n=8) of patients, who were initiall
166 weeks (chronic retrieval cohort), retrieval
was achieved in 91% (
n=10/11) of patients.
167 Technical success
was achieved in 100 of 103 US-guided procedures (97.1%)
168 Prespecified acute procedural end point
was achieved in 12 of 24 (50%) patients: AF termination
169 Clinical response at week 12
was achieved in 14 of 20 (70.0%) control patients, 19 of
170 ellen 20/538, P = .04), retinal reattachment
was achieved in 14 of 20 eyes (70%), and ERM formation w
171 Successful recanalization
was achieved in 14 of 22 occlusion patients (64%) and in
172 Clinical procedural success
was achieved in 160 of 164 patients (97.6%), whereas 4 (
173 nual operation, and device technical success
was achieved in 162 of 164 patients (98.8%).
174 Response
was achieved in 16 of 85 (19%) patients allocated to the
175 f 204 patients (96.6%), and clinical success
was achieved in 174 of 204 (85.3%).
176 HRS reversal
was achieved in 23 of 97 (23.7%) patients receiving terl
177 A VA of >/=20/40
was achieved in 24 of 63 (38%) eyes.
178 ellen 20/538, P = .64), retinal reattachment
was achieved in 25 of 35 eyes (71%), and ERM formation w
179 Chronic isolation (mean, 48+/-16 days)
was achieved in 27 of 36 PVs (75%).
180 of bedaquiline treatment, culture conversion
was achieved in 28 of 29 (97%) cases with culture-positi
181 Globe salvage
was achieved in 2 of 2 group C eyes (100%), 3 of 3 group
182 tinib plus vinorelbine, and clinical benefit
was achieved in 2 of 4 trastuzumab-treated and 0 of 6 tr
183 14 patients, and reattachment of the retina
was achieved in 2 of 5 patients after the first vitrecto
184 pCR
was achieved in 30 of the 85 tumors (35%).
185 In particular, an SVR
was achieved in 31 of 44 (70.5%), 31 of 43 (72.1%), and
186 nual separation without any disruption of DM
was achieved in 335 of 350 donor corneas (95.7%) by use
187 on the 12-lead electrocardiogram at 1 month,
was achieved in 33 of 34 patients.
188 Adequate recanalization
was achieved in 34 of 38 cases (89%).
189 Acutely, PVI
was achieved in 36 of 40 PVs (90%).
190 NSAA >/= 0.1 IU/mL
was achieved in 38 of 41 patients (92.7%) with acceptabl
191 Closure of the MH
was achieved in 39 of 47 eyes (83%) in the study group a
192 Treatment success
was achieved in 3 of 8 children in cohort 1 compared wit
193 l endoscopic clearance of all polyps >/=3 mm
was achieved in 41 of 50 (82%) patients.
194 A pathological complete response
was achieved in 47 of 161 patients (29%) who underwent r
195 and nonsurgical closure of full-thickness MH
was achieved in 4 of 15 eyes (27%).
196 recanalization after endovascular treatment
was achieved in 50 of 54 (92.6%) patients.
197 Technical success
was achieved in 51 of 51 lesions (100%) with DBT VAB ver
198 Bidirectional block
was achieved in 56 of 57 patients in group A (98.2%) and
199 ythmia freedom at 13 months median follow-up
was achieved in 59 of 85 (69%) patients in group I, whic
200 SVR12
was achieved in 62 of the 102 patients (60.8%).
201 Complete spectacle independence
was achieved in 69 of 84 (82.1%) AT LISA 809M recipients
202 Successful access
was achieved in 6 of 10 patients with prior coronary art
203 Permanent resolution of vitreous hemorrhage
was achieved in 6 of 14 patients, and reattachment of th
204 plete clinical resolution of the CIN lesions
was achieved in 87 of the 89 eyes treated (97.75%).
205 A pCR in the primary breast cancer
was achieved in 9 of 51 patients.
206 was well tolerated, and 100% histologic cure
was achieved in 9 of 9 assessable animals without detect
207 Successful outcomes
were achieved in 9 of 14 patients (64%) treated with med
208 ostic rate was 82.9%; unaffected live births
were achieved in 9 of 20 FET cycles (45%), with only one
209 dergo transplantation in CR1 and relapse can
be achieved in 19%
of patients, which is improved by a t
210 a complete ablation of all inducible VTs may
be achieved in 60%
of the cases.
211 oncordance of LV lead with latest site could
be achieved in 85%
of the EG group and occurred fortuito
212 Technical success
was achieved in 100%
of cases.
213 Control of inflammation
was achieved in 100%
of patients.
214 Donor chimerism
was achieved in 20%
of recipients conditioned with MR1/R
215 The primary end point
was achieved in 21%
of the patients in the ruxolitinib g
216 A complete hematologic remission
was achieved in 24%
of patients in the ruxolitinib group
217 Disease stabilization
was achieved in 41%
of patients at EoT (n = 14 of 34 tre
218 A 50% reduction in TLG*
was achieved in 46%
of metastases and in 11 of 30 (37%)
219 Minimal response (MR) or better
was achieved in 47%
of patients (90% confidence interval
220 Successful temporary LVAD weaning
was achieved in 50%
of MPC and 20% of control patients a
221 nse at 6 months (platelets >/=100 x 10(9)/L)
was achieved in 50%
of patients and response at 6 months
222 MFC-MRD negativity, which
was achieved in 51%
of patients after C1 (n = 286) and 6
223 Follow-up of at least 3 years
was achieved in 51%
of patients.
224 A genetic diagnosis
was achieved in 57%
of all familial ataxias.
225 with a complete (R0) resection is 44%, which
was achieved in 59%
of patients.
226 Hematocrit control
was achieved in 60%
of patients receiving ruxolitinib an
227 Good HIV disease control
was achieved in 60%
of the patients (mean, 255 patients)
228 pia (spherical equivalent -0.5 to 0 diopter)
was achieved in 61%
of first DSBCS eyes, 61% of second D
229 The primary outcome
was achieved in 64%
of patients (95% confidence interval
230 First door-to-device </= 120 minutes
was achieved in 65%
of patients (n = 9380); only 37% of
231 arabine and daunorubicin, complete remission
was achieved in 65%
of patients.
232 Revascularization in the embolectomy group
was achieved in 67%
of the patients.
233 The ORR was 95% and a CR
was achieved in 68%
of patients.
234 and 138 the HMII), survival free of any HRAE
was achieved in 69%
of the HM3 group and in 55% of the H
235 Procedural AF termination
was achieved in 70%
of patients, but decreased with long
236 TO
was achieved in 71%
of EVAR and 53% of OSR.
237 a mean follow-up of 19 months, globe salvage
was achieved in 72%
of primary-treated cases and in 62%
238 Treatment success
was achieved in 74%
of patients on 1 immunosuppressant,
239 First-attempt success
was achieved in 74%
of the Glidescope video laryngoscopy
240 of 42 months, complete hematologic response
was achieved in 76%
of patients with PV and 77% of those
241 A partial response or better
was achieved in 79%
of patients in the treatment group a
242 Overall acute success
was achieved in 81%
of the patients.
243 abbit hearts, the successful induction of VF
was achieved in 83%
of attempts in controls versus 41% i
244 rate was 67%, and at least minimal response
was achieved in 83%
of the patients.
245 At week 48, virologic success
was achieved in 85%
of COBI recipients and 87% of RTV re
246 lation (systolic blood pressure >/=60 mm Hg)
was achieved in 85%
of the dantrolene group in compariso
247 Complete response
was achieved in 89%
of older patients, 3% had progressiv
248 12 weeks after treatment completion (SVR12)
was achieved in 90%
of patients (95% confidence interval
249 CC TVT Registry, device implantation success
was achieved in 92%
of cases, the overall in-hospital mo
250 increase in Hb of >/=1.0 g/dl from baseline)
was achieved in 96%
of efficacy-evaluable patients.
251 d in 53% of patients, and complete responses
were achieved in 21%
of patients.
252 nds, in which rank-1 sum formula assignments
were achieved in 84%
of the cases, compared to only 63%
253 A reduction of concomitant medication
was achieved in 1 patient.
254 A definitive diagnosis could
be achieved in 37 patients with 39 MDCT masses (22 throm
255 Complete ablation
was achieved in 10 patients (83.3%), and the alpha-fetop
256 PS-R0-neck
was achieved in 1196 patients (85.5%), 131 patients (9.3
257 Native biventricular circulation
was achieved in 12 patients after staged LV recruitment;
258 Resolution of diarrhea
was achieved in 14 patients (70%) after a single FMT (8
259 Resolution of diarrhea
was achieved in 14 patients (70%; 95% CI, 47%-85%) after
260 The primary end point
was achieved in 164 patients in the study group and 85 p
261 cess (noninducibility of any monomorphic VT)
was achieved in 17 patients (38%), partial success (elim
262 A successful resection
was achieved in 194 patients (82%) in the laparoscopic s
263 Complete remission
was achieved in 23 patients (18%), 36 (27%) had a partia
264 Stable disease
was achieved in 23 patients.
265 Complete remission or partial remission
was achieved in 247 patients (76%).
266 Complete response
was achieved in 24 patients (complete response rate, 63%
267 events (26%) for which return of circulation
was achieved in 25 patients (93%).
268 and reduction of MR from 3+ or 4+ to </=2+)
was achieved in 26 patients (86.7%).
269 Complete remission
was achieved in 27 patients (90%), including 2 patients
270 Successful device implantation
was achieved in 28 patients (93.3%).
271 A successful resection
was achieved in 292 patients (50.8%).
272 Sustained disease remission
was achieved in 2 patients undergoing HSCT (8.7%) vs 1 c
273 Four-hour survival
was achieved in 307 patients (23.6%) with mechanical CPR
274 pCR
was achieved in 30 patients (22%); 37% SCC and 17% adeno
275 Spectacle independency for distance vision
was achieved in 31 patients (84%) in the toric group com
276 Clinical benefit
was achieved in 31 patients treated for one infection an
277 Complete resection (stages I and II)
was achieved in 32 patients, and 28 patients had stage I
278 Complete tumor resection
was achieved in 34 patients (40%), including seven of th
279 artial, or minor response or stable disease)
was achieved in 47 patients (87.0%).
280 R0 resection
was achieved in 53 patients (94.6%).
281 he IP maneuver, complete CTI block (phase 2)
was achieved in 59 patients, in 13 of whom an intermedia
282 response 12 weeks after the end of treatment
was achieved in 6 patients (60%).
283 Termination of VT
was achieved in 6 patients at a mean ventricular activat
284 Globe preservation
was achieved in 80 patients (97.6%); 2 patients underwen
285 with afatinib monotherapy, clinical benefit
was achieved in 9 patients (35%), 0 of 7 trastuzumab-tre
286 A successful NJEEN
was achieved in 63%
patients.
287 309 ablation procedures in 277 patients and
was achieved in 291 procedures (94%).
288 atural tubulin polymerization inhibitor, has
been achieved in 12 steps starting from commercially ava
289 -methylwelwitindolinone D isonitrile (1) has
been achieved in 17 steps from a readily available carvo
290 selective synthesis of (-)-himalensine A has
been achieved in 22 steps.
291 The total synthesis of (+)-cryptocaryol A
was achieved in 20 steps from (R)-glycidol.
292 e asymmetric synthesis of (-)-(S,S)-homaline
was achieved in 8 steps and 18% overall yield, and the a
293 asymmetric synthesis of (-)-(R,R)-hopromine
was achieved in 9 steps and 23% overall yield, from comm
294 lete success with IOP </= 21 mmHg at 8 years
was achieved in 48 subjects (55.8%) in the 5-FU and 33 s
295 Complete anatomic success
was achieved in 61 subjects (53.5%), of whom 55 needed o
296 Weight loss or stabilization
was achieved in 96%
subjects receiving TORe and 78% of c
297 control with resolution of subretinal fluid
was achieved in 7 tumors (78%), with mean tumor thicknes
298 0% versus 4% (P = .925), and stable disease
was achieved in 35%
versus 17% of patients (P = .021).
299 rst significant step forward in clinical use
was achieved in 2008 with the first human experience wit
300 Intact TME specimens
were achieved in 85%,
with minor defects in 11% and majo